Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells

Journal of Biological Chemistry

Volumn 288, Issue 17, 2013, Pages 11676-11688

  Hix, Laura M ^a   Karavitis, John ^a   Khan, Mohammad W ^a   Shi, Yihui H ^a   Khazaie, Khashayarsha ^a   Zhang, Ming ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER CELLS; CONSTITUTIVELY ACTIVES; DISEASE PROGRESSION; DUCTAL CARCINOMA IN SITU; HUMAN BREAST CANCER; MAMMARY CARCINOMA CELL; MICROARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

CELLS; CHEMICAL ACTIVATION; CYTOLOGY; DISEASES; MAMMALS; TRANSCRIPTION; TRANSCRIPTION FACTORS;

TUMORS;

CD33 ANTIGEN; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER TRANSPLANTATION; CARCINOMA CELL; CARCINOMA IN SITU; CD33+ MYELOID CELL; CELL FUNCTION; CELL STRAIN; CELL STRAIN TM40D; CELL STRAIN TM40D MB; CONTROLLED STUDY; DISEASE ACTIVITY; GENE SILENCING; IMMOBILIZED CELL; IMMUNE DEFICIENCY; INVASIVE CARCINOMA; METASTASIS POTENTIAL; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNE TOLERANCE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, KNOCKOUT; MYELOID CELLS; NEOPLASM PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 3; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

MUS;

EID: 84876921278     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.441402     Document Type: Article

References (64)

1. American Cancer Society. Breast Cancer Facts & Figures 2009-2010. American Cancer Society, Inc., Atlanta
2. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. (2002) Cancer immunoediting. From immunosurveillance to tumor escape. Nat Immunol. 3, 991-998
3. Khong, H. T., and Restifo, N. P. (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3, 999-1005
4. Coussens, L. M., and Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867
5. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011) Natural innate and adaptive immunityto cancer. Annu. Rev. Immunol. 29, 235-271
6. Gross, S., and Walden, P. (2008) Immunosuppressivemechanisms in human tumors. Why we still cannot cure cancer. Immunol. Lett. 116, 7-14
7. Karavitis, J., Hix, L. M., Shi, Y. H., Schultz, R. F., Khazaie, K., and Zhang, M. (2012) Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PloS One 7, e46342
8. Brooks, B., Bundred, N. J., Howell, A., Lang, S. H., and Testa, N. G. (1997) Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis. Int. J. Cancer 73, 690-696
9. Li, Z., Schem, C., Shi, Y. H., Medina, D., and Zhang, M. (2008) Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin. Exp. Metastasis 25, 389-400
10. Hix, L. M., Shi, Y. H., Brutkiewicz, R. R., Stein, P. L., Wang, C. R., and Zhang, M. (2011) CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PloS One 6, e20702
11. Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., CarverMoore, K., DuBois, R. N., Clark, R., Aguet, M., and Schreiber, R. D. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442
12. Durbin, J. E., Hackenmiller, R., Simon, M. C., and Levy, D. E. (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84, 443-450
13. Lynch, R. A., Etchin, J., Battle, T. E., and Frank, D. A. (2007) A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-γ in human cancer cells. Cancer Res. 67, 1254-1261
14. Manavi, M., Hudelist, G., Fink-Retter, A., Gschwandtler-Kaulich, D., Pis-chinger, K., and Czerwenka, K. (2007) Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol. 105, 418-426
15. Khodarev, N., Ahmad, R., Rajabi, H., Pitroda, S., Kufe, T., McClary, C., Joshi, M. D., MacDermed, D., Weichselbaum, R., and Kufe, D. (2010) Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 29, 920-929
16. Kovacic, B., Stoiber, D., Moriggl, R., Weisz, E., Ott, R. G., Kreibich, R., Levy, D. E., Beug, H., Freissmuth, M., and Sexl, V. (2006) STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10, 77-87
17. Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C., Lashkari, D., Shalon, D., Brown, P. O., and Botstein, D. (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. U. S. A. 96, 9212-9217
18. Khodarev, N. N., Beckett, M., Labay, E., Darga, T., Roizman, B., and Weichselbaum, R. R. (2004) STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl. Acad. Sci. U. S. A. 101, 1714-1719
19. Khodarev, N. N., Minn, A. J., Efimova, E. V., Darga, T. E., Labay, E., Beckett, M., Mauceri, H. J., Roizman, B., and Weichselbaum, R. R. (2007) Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. CancerRes. 67, 9214-9220
20. Weichselbaum, R. R., Ishwaran, H., Yoon, T., Nuyten, D. S., Baker, S. W., Khodarev, N., Su, A. W., Shaikh, A. Y., Roach, P., Kreike, B., Roizman, B., Bergh, J., Pawitan, Y., van de Vijver, M. J., and Minn, A. J. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl Acad. Sci. U. S. A. 105, 18490-18495
21. de Prati, A. C., Ciampa, A. R., Cavalieri, E., Zaffini, R., Darra, E., Menegazzi, M., Suzuki, H., and Mariotto, S. (2005) STAT1 asanewmolecular target of anti-inflammatorytreatment. Curr. Med. Chem. 12, 1819-1828
22. Serafini, P., Borrello, I., and Bronte, V. (2006) Myeloid suppressor cells in cancer. Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65
23. Gabrilovich, D. I., and Nagaraj, S. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174
24. DeNardo, D. G., and Coussens, L. M. (2007) Inflammation and breast cancer. Balancing immune response. Cross-talk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9, 212
25. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., and Van Ginderachter, J. A. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244
26. Shi, H. Y., Zhang, W., Liang, R., Abraham, S., Kittrell, F. S., Medina, D., and Zhang, M. (2001) Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res. 61, 6945-6951
27. Shi, H. Y., Zhang, W., Liang, R., Kittrell, F., Templeton, N. S., Medina, D., and Zhang, M. (2003) Modeling human breast cancer metastasis in mice. Maspin as a paradigm. Histol. Histopathol. 18, 201-206
28. Tanaka, K., Koga, Y., Taniguchi, K., Kamikaseda, K., and Nomoto, K. (1986) T cell recruitment from the thymus to the spleen in tumor-bearing mice. I. Analysis of recruited cells by surface markers. Cancer Immunol. Immunother. 22, 37-42
29. Khodarev, N. N., Roizman, B., and Weichselbaum, R. R. (2012) Molecular pathways. Interferon/stat1 pathway. Role in the tumor resistance to geno-toxic stress and aggressive growth. Clin. Cancer Res. 18, 3015-3021
30. Buess, M., Nuyten, D. S., Hastie, T., Nielsen, T., Pesich, R., and Brown, P. O. (2007) Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol. 8, R191
31. Bui, J. D., and Schreiber, R. D. (2007) Cancer immunosurveillance, immu-noediting and inflammation. Independent or interdependent processes? Curr. Opin. Immunol. 19, 203-208
32. Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., and Ostrand Rosenberg, S. (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019-10026
33. Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., and Bronte, V. (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238-244
34. Ochoa, A. C., Zea, A. H., Hernandez, C., and Rodriguez, P. C. (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13, 721s-726s
35. Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., and Gabrilovich, D. I. (2001) Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689
36. Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., and Montero, A. J. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59
37. Melani, C., Chiodoni, C., Forni, G., and Colombo, M. P. (2003) Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145
38. Li, J., Yu, B., Song, L., Eschrich, S., and Haura, E. B. (2007) Effects of IFN-7 and Stat1 on gene expression, growth, and survival in non-small cell lung cancer cells. J. Interferon Cytokine Res. 27, 209-220
39. Cheon, E. C., Khazaie, K., Khan, M. W., Strouch, M. J., Krantz, S. B., Phillips, J., Blatner, N. R., Hix, L. M., Zhang, M., Dennis, K. L., Salabat, M. R., Heiferman, M., Grippo, P. J., Munshi, H. G., Gounaris, E., and Bentrem, D. J. (2011) Mast cell 5-lipoxygenase activitypromotes intestinal polyposis in APCA468 mice. Cancer Res. 71, 1627-1636
40. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008) Cancer-related inflammation. Nature 454, 436-444
41. Lechner, M. G., Liebertz, D. J., and Epstein, A. L. (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J. Immunol. 185, 2273-2284
42. Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., and Schreiber, R. D. (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907
43. Huang, B., Pan, P. Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., and Chen, S. H. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131
44. Khazaie, K., and von Boehmer, H. (2006) The impact of CD4CD25 Treg on tumor specific CD8 T cell cytotoxicity and cancer. Semin. Cancer Biol. 16, 124-136
45. Wang, H. Y., and Wang, R. F. (2007) Regulatory T cells and cancer. Curr Opin. Immunol. 19, 217-223
46. Critchley-Thorne, R. J., Yan, N., Nacu, S., Weber, J., Holmes, S. P., and Lee, P. P. (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 4, e176
47. Simons, D. L., Lee, G., Kirkwood, J. M., and Lee, P. P. (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J. Transl. Med. 9, 52
48. Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., and Schreiber, R. D. (2001) IFN7 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111
49. Chan, S. R., Vermi, W., Luo, J., Lucini, L., Rickert, C., Fowler, A. M., Lonardi, S., Arthur, C., Young, L. J., Levy, D. E., Welch, M. J., Cardiff, R. D., and Schreiber, R. D. (2012) STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinomas. Breast Cancer Res. 14, R16
50. Schultz, J., Koczan, D., Schmitz, U., Ibrahim, S. M., Pilch, D., Landsberg, J., and Kunz, M. (2010) Tumor-promoting role of signal transducer and activator of transcription (Stat) 1 in late-stage melanoma growth. Clin. Exp. Metastasis 27, 133-140
51. Ohmori, Y., and Hamilton, T. A. (2001) Requirement for STAT1 in LPS-induced gene expression in macrophages. J. Leukoc. Biol. 69, 598-604
52. Xuan, Y. T., Guo, Y., Zhu, Y., Han, H., Langenbach, R., Dawn, B., and Bolli, R. (2003) Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J. Mol Cell Cardiol 35, 525-537
53. Kaur, T., Mukherjea, D., Sheehan, K., Jajoo, S., Rybak, L. P., and Ramku-mar, V. (2011) Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis. 2, e180
54. Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., and Schreiber, R. D. (1998) Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 95, 7556-7561
55. Lee, C. K., Rao, D. T., Gertner, R., Gimeno, R., Frey, A. B., and Levy, D. E. (2000) Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165, 3571-3577
56. Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., and Apte, R. N. (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J. Immunol. 175, 8200-8208
57. Youn, J. I., Nagaraj, S., Collazo, M., and Gabrilovich, D. I. (2008) Subsets of myeloid-derived suppressor cells in tumor-bearingmice. J. Immunol. 181, 5791-5802
58. Lin, W. J., and Yeh, W. C. (2005) Implication of Toll-like receptor and tumor necrosis factor a signaling in septic shock. Shock 24, 206-209
59. Mocellin, S., Rossi, C. R., Pilati, P., and Nitti, D. (2005) Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 16, 35-53
60. Eyles, J., Puaux, A. L., Wang, X., Toh, B., Prakash, C., Hong, M., Tan, T. G., Zheng, L., Ong, L. C., Jin, Y., Kato, M., Prevost-Blondel, A., Chow, P., Yang, H., and Abastado, J. P. (2010) Tumor cells disseminate early, but immu-nosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J. Clin. Invest. 120, 2030-2039
61. Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V. M., Marin, S., Alhava, E., and Syrjanen, K. (1992) Lymphocyteinfiltrates as aprognosticvariable in female breast cancer. Eur. J. Cancer 28A, 859-864
62. Demaria, S., Volm, M. D., Shapiro, R. L., Yee, H. T., Oratz, R., Formenti, S. C., Muggia, F., and Symmans, W. F. (2001) Development of tumorinfiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 7, 3025-3030
63. deLeeuw, R. J., Kost, S. E., Kakal, J. A., and Nelson, B. H. (2012) The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer. A critical review of the literature. Clin. Cancer Res. 18, 3022-3029
64. Handel-Fernandez, M. E., Ilkovitch, D., Iragavarapu-Charyulu, V., Herbert, L. M., and Lopez, D. M. (2009) Decreased levels of both Statl and Stat3 in T lymphocytes from mice bearing mammary tumors. Anticancer Res. 29, 2051-2058